| 5.75 -0.36 (-5.89%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.22 |
1-year : | 8.38 |
| Resists | First : | 6.18 |
Second : | 7.17 |
| Pivot price | 5.87  |
|||
| Supports | First : | 4.57 |
Second : | 3.8 |
| MAs | MA(5) : | 6.15 |
MA(20) : | 5.61 |
| MA(100) : | 5.29 |
MA(250) : | 5.99 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 55.6 |
D(3) : | 61.3 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 12.35 | Low : | 3.78 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RXRX ] has closed above bottom band by 43.3%. Bollinger Bands are 47.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.32 - 6.36 | 6.36 - 6.4 |
| Low: | 5.49 - 5.52 | 5.52 - 5.56 |
| Close: | 5.68 - 5.74 | 5.74 - 5.81 |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Wed, 22 Oct 2025
Growth or Bubble? Decoding Recursion Pharmaceuticals Stock - StocksToTrade
Wed, 22 Oct 2025
Recursion Pharmaceuticals Stock: Growth or Bubble? - StocksToTrade
Wed, 22 Oct 2025
Jim Cramer on Recursion Pharmaceuticals: “Now, It’s a Meme Stock” - Yahoo Finance
Tue, 21 Oct 2025
Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings - Insider Monkey
Tue, 21 Oct 2025
Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings - Yahoo Finance
Tue, 21 Oct 2025
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Navigating the Biotech Frontier with a 33.3% Revenue Surge - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 430 (M) |
| Shares Float | 416 (M) |
| Held by Insiders | 4.7 (%) |
| Held by Institutions | 69.3 (%) |
| Shares Short | 133,410 (K) |
| Shares Short P.Month | 124,080 (K) |
| EPS | -1.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.11 |
| Profit Margin | 0 % |
| Operating Margin | -916.8 % |
| Return on Assets (ttm) | -39.1 % |
| Return on Equity (ttm) | -86.4 % |
| Qtrly Rev. Growth | 33.2 % |
| Gross Profit (p.s.) | -1.01 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -1.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -383 (M) |
| Levered Free Cash Flow | -186 (M) |
| PE Ratio | -3.18 |
| PEG Ratio | 0 |
| Price to Book value | 2.71 |
| Price to Sales | 38.24 |
| Price to Cash Flow | -6.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|